Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

Conexeu Sciences Inc. (NASDAQ: CNXU), a preclinical-stage regenerative-tissue company that began trading weeks earlier, expanded its board from six to nine directors on June 15, 2026, and promoted co-founder David Bogart to Chief Commercial Officer, adding executives from Kyowa Kirin, Allergan, Novartis, and major investment banks as it pursues a targeted early-2027 FDA 510(k) submission for its CXU™ platform.